Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors

Information

  • Research Project
  • 8580801
  • ApplicationId
    8580801
  • Core Project Number
    U43CA179506
  • Full Project Number
    1U43CA179506-01
  • Serial Number
    179506
  • FOA Number
    PAR-10-286
  • Sub Project Id
  • Project Start Date
    7/1/2014 - 10 years ago
  • Project End Date
    3/31/2016 - 9 years ago
  • Program Officer Name
    KURTZ, ANDREW J.
  • Budget Start Date
    7/1/2014 - 10 years ago
  • Budget End Date
    3/31/2016 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
  • Award Notice Date
    6/17/2014 - 10 years ago

Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors

DESCRIPTION (provided by applicant): There are very limited options currently available for the treatment of HPV(-) head and neck squamous cell cancer (HNSCC), the sixth leading cause of cancer in the United States and worldwide. HNSCC, like most forms of cancer, is dependent on angiogenesis, the growth of blood vessels. We have developed a mimetic multimodal peptide that inhibits growth of tumor angiogenesis and directly inhibits tumor cell adhesion and migration. Tumors treated with this multimodal peptide are less likely to develop resistance to therapy because it inhibits signals from a broad range of tumor-secreted factors. In this project we will create a novel targeted nanoparticle delivery vehicle for this peptide. The nanoparticle-encapsulated peptide will be administered systemically and will accumulate in the tumor and its vasculature in order to enhance both efficacy and safety. Successful completion of the project will result in the creation of a powerful, new therapeutic for the treatment of HNSCC and also help a startup biotechnology company reach a critical milestone.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    258009
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:258009\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ASCLEPIX THERAPEUTICS, LLC
  • Organization Department
  • Organization DUNS
    968267299
  • Organization City
    LUTHERVILLE
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    210931702
  • Organization District
    UNITED STATES